For the quarter ending 2025-09-30, PGNY had $2,438K increase in cash & cash equivalents over the period. $45,987K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 13,864 | 32,171 |
| Deferred tax expense | 8 | 23 |
| Foreign currency exchange rate loss | - | 0 |
| Non-cash interest expense | 279 | - |
| Depreciation and amortization | 1,268 | 2,313 |
| Loss on disposal of property and equipment | 0 | -79 |
| Stock-based compensation expense | 32,173 | 64,895 |
| Bad debt expense | 4,328 | 11,017 |
| Net accretion of discounts on marketable securities | 459 | -27 |
| Accounts receivable | -15,011 | 47,166 |
| Prepaid expenses and other current assets | 6,913 | 7,946 |
| Accounts payable | -17,547 | 45,207 |
| Accrued expenses and other current liabilities | 7,465 | 5,852 |
| Non-cash interest income | - | 0 |
| Other noncurrent assets and liabilities | -1,194 | 1,154 |
| Net cash provided by operating activities | 50,671 | 105,318 |
| Purchase of property and equipment, net | 4,684 | 8,112 |
| Purchase of marketable securities | 111,425 | 200,088 |
| Sale of marketable securities | 73,365 | 93,015 |
| Acquisition of business, net of cash acquired | 0 | 9,340 |
| Net cash (used in) provided by investing activities | -42,744 | -124,525 |
| Repurchase of common stock | 0 | 0 |
| Proceeds from exercise of stock options | 5 | 18 |
| Issuance costs on credit facility | 3,087 | - |
| Payment of employee taxes related to equity awards | 2,625 | 6,195 |
| Proceeds from contributions to employee stock purchase plan | 221 | 560 |
| Net cash used in financing activities | -5,486 | -5,617 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -3 | 52 |
| Net decrease in cash, cash equivalents, and restricted cash | 2,438 | -24,772 |
| Cash and cash equivalents at beginning of period | 162,314 | - |
| Cash and cash equivalents at end of period | 139,980 | - |
Progyny, Inc. (PGNY)
Progyny, Inc. (PGNY)